Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av ASP3082 hos voksne med tidligere behandlede solide svulster

13. oktober 2026 oppdatert av: Astellas Pharma Inc

En fase 1-studie av ASP3082 hos deltakere med tidligere behandlede lokalt avanserte eller metastatiske solide tumorer med KRAS G12D-mutasjon

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D.

This study will be in 2 parts.

In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2.

In Part 2, ASP3082 will be given in by itself, or in combination with the other study treatments.

Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

681

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope National Medical Center
      • Santa Monica, California, Forente stater, 90404
        • Rekruttering
        • UCLA Santa Monica Hematology Oncology
    • Colorado
      • Denver, Colorado, Forente stater, 80218
        • Rekruttering
        • Denver HealthONE Drug Development Unit
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06520-8028
        • Rekruttering
        • Smilow Cancer Center at Yale New Haven Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20007
        • Rekruttering
        • Georgetown University Hospital
    • Florida
      • Gainesville, Florida, Forente stater, 32610
        • Rekruttering
        • University of Florida, Davis Cancer Center
      • Lake Mary, Florida, Forente stater, 32746
        • Avsluttet
        • Florida Cancer Specialist
      • Sarasota, Florida, Forente stater, 34232-6422
        • Rekruttering
        • Florida Cancer Specialists & Research Institute Sarasota
    • Kansas
      • Westwood, Kansas, Forente stater, 66205
        • Rekruttering
        • University of Kansas Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Dana Farber Cancer Institute
    • Michigan
      • Ypsilanti, Michigan, Forente stater, 48197
        • Rekruttering
        • Trinity Health Ann Arbor Hospital
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601
        • Rekruttering
        • Hackensack University Medical Center
    • New York
      • Buffalo, New York, Forente stater, 14263
        • Rekruttering
        • Roswell Park Cancer Institute
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Forente stater, 10032
        • Avsluttet
        • Columbia University - Herbert Irving Comprehensive Cancer Center
      • Rochester, New York, Forente stater, 14642
        • Rekruttering
        • University of Rochester Medical Center James P. Wilmot Cancer Center
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • Case Western
      • Maumee, Ohio, Forente stater, 43537
        • Rekruttering
        • Taylor Cancer Research Center
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Rekruttering
        • Oregon Health and Science University
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Vanderbilt University Medical Center
      • Nashville, Tennessee, Forente stater, 37203
        • Avsluttet
        • SCRI Oncology Partners
    • Texas
      • San Antonio, Texas, Forente stater, 78229
        • Rekruttering
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • NEXT Oncology - Virginia Cancer Specialists
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
        • Rekruttering
        • University of Wisconsin Hospital
      • Bordeaux, Frankrike
        • Rekruttering
        • Site FR33002
      • Lyon, Frankrike
        • Rekruttering
        • Site FR33001
      • Lyon, Frankrike
        • Rekruttering
        • Site FR33005
    • Grenobele
      • La Tronche, Grenobele, Frankrike
        • Rekruttering
        • Site FR33003
    • Île-de-France Region
      • Villejuif, Île-de-France Region, Frankrike
        • Rekruttering
        • Site FR33004
      • Osaka, Japan
        • Rekruttering
        • Osaka International Cancer Institute
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan
        • Rekruttering
        • Aichi Cancer Center
    • Chiba
      • Kashiwa, Chiba, Japan
        • Rekruttering
        • National Cancer Center Hospital East
    • Ehime
      • Matsuyama, Ehime, Japan
        • Rekruttering
        • Shikoku Cancer Center
    • Fukuoka
      • Kurume, Fukuoka, Japan
        • Rekruttering
        • Kurume University Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japan
        • Rekruttering
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japan
        • Rekruttering
        • Kanagawa Cancer Center
    • Miyagi
      • Sendai, Miyagi, Japan
        • Rekruttering
        • Tohoku University Hospital
    • Niigata
      • Niigata, Niigata, Japan
        • Rekruttering
        • Niigata Cancer Center Hospital
    • Osaka
      • Hirakata, Osaka, Japan
        • Rekruttering
        • Kansai Medical University Hospital
      • Sayama, Osaka, Japan
        • Rekruttering
        • Kindai University Hospital
    • Shizuoka
      • Sunto-gun, Shizuoka, Japan
        • Rekruttering
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo-ku, Tokyo, Japan
        • Avsluttet
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Japan
        • Rekruttering
        • Cancer Institute Hospital of JFCR
    • Yamaguchi
      • Ube, Yamaguchi, Japan
        • Rekruttering
        • Yamaguchi University Hospital
      • Shanghai, Kina
        • Rekruttering
        • Shanghai Pulmonary Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • Rekruttering
        • Beijing Cancer Hospital
    • Shanghai Municipality
      • Xuhui District, Shanghai Municipality, Kina
        • Rekruttering
        • Fudan University Shanghai Cancer Center
      • San Juan, Puerto Rico, 00935
        • Rekruttering
        • PanOncology Trials
      • A Coruña, Spania
        • Rekruttering
        • Site ES34009
      • Barcelona, Spania
        • Rekruttering
        • Site ES34001
      • Barcelona, Spania
        • Rekruttering
        • Site ES34008
      • Barcelona, Spania
        • Rekruttering
        • Site ES34005
      • Madrid, Spania
        • Rekruttering
        • Site ES34004
      • Madrid, Spania
        • Rekruttering
        • Site ES34007
      • Madrid, Spania
        • Rekruttering
        • Site ES34006
      • Málaga, Spania
        • Rekruttering
        • Site ES34002
      • Seville, Spania
        • Rekruttering
        • Site ES34003
      • Valencia, Spania
        • Rekruttering
        • Site ES34010
    • Navarre
      • Pamplona, Navarre, Spania
        • Rekruttering
        • Site ES34011
      • Seoul, Sør -Korea
        • Rekruttering
        • Site KR82006
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Sør -Korea
        • Rekruttering
        • Site KR82005
      • Seongnam-si, Gyeonggi-do, Sør -Korea
        • Rekruttering
        • Site KR82002
    • North Chungcheong
      • Cheongju-si, North Chungcheong, Sør -Korea
        • Rekruttering
        • Site KR82007
    • Seoul
      • Jongno -Gu, Seoul, Sør -Korea
        • Rekruttering
        • Site KR82001
      • Seodaemun-gu, Seoul, Sør -Korea
        • Rekruttering
        • Site KR82003
      • Songpa-gu, Seoul, Sør -Korea
        • Rekruttering
        • Site KR82004

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Participant has locally advanced (unresectable) or metastatic solid tumor malignancy with documented Kirsten rat sarcoma viral oncogene homolog [KRAS] G12D mutation and has received prior standard therapy and the investigator does not see any further clinical benefit from continuing such targeted therapy, or is ineligible to receive standard approved therapies (no limit to the number of prior treatment regimens).

  • For the ASP3082 monotherapy escalation cohorts, participants with solid tumor malignancies are allowed to be enrolled. Participants with other known KRAS G12 mutations will not be eligible for the study

  • For ASP3082 combination therapy with Nab-P+GEM or FOLFIRINOX or NALRIFOX: Participant must have mPDAC that has not been previously treated with chemotherapy. If a participant received (neo)adjuvant therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the (neo)adjuvant therapy.

  • Participant consents to provide tumor specimen in a tissue block or unstained serial slides or a tumor biopsy (core needle biopsy or excision) obtained after the last interventional treatment, but prior to start of study intervention. Participant also consents to provide a sample for tumor biopsy during the treatment period as indicated in the study protocol. If a participant cannot provide a fresh tissue biopsy sample, the site should consult with the sponsor/study medical monitor.

  • Participant has at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

  • Participant has an ECOG performance status of 0, 1 or 2 for dose escalation, and 0 or 1 for dose expansion.

  • Participant's last dose of prior antineoplastic therapy, including any immunotherapy, was 21 days or 5 half-lives, whichever is shorter, prior to initiation of study intervention administration.

  • Participant has completed any radiotherapy (including stereotactic radiosurgery) at least 14 days prior to the start of study intervention administration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids (NOTE: Physiologic replacement dose of hydrocortisone or its equivalent [defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone, or up to 10 mg per day of prednisone] is permitted), and not have active radiation pneumonitis. A 1-week washout is permitted for palliative radiation (<= 2 weeks of radiotherapy) to non-central nervous system disease.

  • Participant's adverse events [AEs] (excluding alopecia) from prior therapy have improved to grade 1 or baseline within 14 days prior to start of study intervention (or prior to staring SoC chemotherapy, for first line (1L) participants receiving Nab-P+GEM FOLFIRINOX or NALIRIFOX.

  • Participant has adequate organ function as indicated by protocol laboratory value parameters (If a participant has received a recent blood transfusion, the laboratory tests must be obtained >= 14 days after any blood transfusion.).

  • Female participant is not pregnant, confirmed by pregnancy test and medical evaluation by interview, and at least 1 of the following conditions apply:

    • Not a woman of childbearing potential (WOCBP).
    • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after study intervention administration.
    • EU only: For combination therapy with carboplatin, follow contraception guidelines from the time of informed consent through at least 7 months after the final dose of carboplatin.
    • South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 15 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 14 months after the final dose of cisplatin.
  • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 6 months after study intervention administration.

  • Female participant must not donate ova starting at first dose of study intervention and throughout the study period and for 6 months after study intervention administration.

  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 3 months after study intervention administration.

  • Male participant must not donate sperm during the treatment period and for 3 months after study intervention administration.

  • South Korea only: For combination therapy with oxaliplatin, follow contraception guidelines from the time of informed consent through at least 12 months after the final dose of oxaliplatin. For combination therapy with cisplatin, follow contraception guidelines from the time of informed consent through at least 11 months after the final dose of cisplatin.

  • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 3 months after study intervention administration.

  • Participant agrees not to participate in another interventional study while receiving study intervention (Participants who are currently in the follow-up period of an interventional clinical trial are allowed).

  • For ASP3082 Combination Therapy with Pembrolizumab (Cohort G), or Platinum-based Chemotherapy + Pemetrexed +/- Pembrolizumab (Cohort H): Participant must have pathologically documented locally advanced or metastatic (unresectable Stage IIIB-IV) non-small cell lung cancer (NSCLC) (Note: for Cohort H only, the tumor must be non-squamous NSCLC) with KRAS G12D mutation and

    • have received prior platinum-containing chemotherapy (safety lead-in only) or
    • have never received systemic therapy (up to 1 cycle of SoC pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort G and up to 1 cycle of SoC platinum-based chemotherapy ± pembrolizumab [defined as one 21-day cycle of 200 mg] or pembrolizumab [defined as one 21-day cycle of 200 mg] in Cohort H is permitted prior to Screening, provided a 21-day washout occurs before C1D1) for locally advanced or metastatic NSCLC with no oncogenic driver mutations. Participants who received adjuvant or neoadjuvant platinum-based chemotherapy and developed recurrent or metastatic disease more than 12 months after completing therapy may be enrolled.

Exclusion Criteria:

  • Participant has received investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to start of study intervention.
  • Participant has symptomatic or untreated central nervous system (CNS) metastases. Participants with asymptomatic, treated CNS metastases are eligible.
  • Participant has leptomeningeal disease as a manifestation of the current malignancy.
  • Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.
  • Participant has a known or suspected hypersensitivity to ASP3082 or any components of the formulation used.
  • Participant with active hepatitis B (including acute hepatitis B virus [HBV] or chronic HBV) or hepatitis C virus [HCV] (ribonucleic acid [RNA] detected by qualitative assay). HCV RNA testing is not required in participants with negative HCV antibody testing.
  • Participant has a known history of human immunodeficiency virus [HIV] infection. No HIV testing is required unless mandated by a local health authority.
  • Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of study intervention, left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO) or currently has an uncontrolled illness including, but not limited to symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, obligate use of a cardiac pacemaker, or long QT syndrome.
  • Participant has a corrected QT interval (single electrocardiogram [ECG]) using Fridericia's formula (QTcF) > 450 milliseconds (msec) (men) or >470 msec (women) during screening.
  • Participant has received prior treatment with a specific KRAS G12D inhibitor/degrader or pan-RAS inhibitor/degrader targeting KRAS G12D. Participants who received prior treatment with a KRAS G12D inhibitor/degrader are eligible for the ASP3082 combination therapy cohort.
  • Participant has an active infection requiring intravenous antibiotics within 14 days prior to study intervention.
  • Participant is expected to require another form of antineoplastic therapy while on study treatment.
  • Participant has any condition which makes the participant unsuitable for study participation (such as psychiatric illness/social situations that would limit compliance with study requirements).
  • Participant has had major surgery within 4 weeks prior to first dose of study intervention.

For ASP3082 Combination Therapy:

  • Prior discontinuation of cetuximab treatment due to toxicity or intolerance of cetuximab.
  • History of interstitial lung disease requiring systemic steroid treatment. Note that a participant with resolved pulmonary infections or radiation pneumonitis is eligible.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: ASP3082 Dose Escalation (Monotherapy Part 1)

Participants will receive ASP3082 in a 21-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082
Eksperimentell: ASP3082 Dose Expansion (Monotherapy Part 2)

Participants will receive ASP3082 with dose level(s) selected from dose escalation (part 1) in a 21-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082
Eksperimentell: ASP3082 + Cetuximab Dose Escalation (Combination Therapy Part 1)

Participants will receive ASP3082 in a 21-day cycle. Cetuximab will be administered weekly.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Eksperimentell: ASP3082 + Cetuximab Dose Expansion (Combination Therapy Part 2)

Participants will receive ASP3082 or ASP3082 + Cetuximab with dose level(s) selected from dose escalation (part 1) in a 21-day cycle. Cetuximab will be administered weekly.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Eksperimentell: ASP3082 China Safety Cohort

Participants will receive ASP3082 with dose level selected from dose escalation (Monotherapy part 1) in a 21-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082
Eksperimentell: Treatment naive PDAC cohort ASP3082 + FOLFIRINOX

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with FOLFIRINOX (leucovorin [LV]/fluorouracil [5-FU]/irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Eksperimentell: Treatment naive PDAC cohort ASP3082 + Nab-Paclitaxel + Gemcitabine

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with Nab-P + GEM (nanoparticle albumin-bound-paclitaxel plus gemcitabine) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Eksperimentell: ASP3082 + Docetaxel - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with docetaxel in a 21-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Eksperimentell: ASP3082 + Pembrolizumab - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with pembrolizumab in a 21-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Eksperimentell: ASP3082 + (Cisplatin or Carboplatin) and Pemetrexed +/- Pembrolizumab - NSCLC

Participants with KRAS G12D mutant will receive ASP3082 in combination with platinum-based chemotherapy (cisplatin or carboplatin) and pemetrexed, with or without pembrolizumab in a 21-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Eksperimentell: Treatment naive PDAC cohort ASP3082 + NALIRIFOX

Upon completion of dose escalation (part 1), participants with KRAS G12D mutant will receive ASP3082 in combination with NALIRIFOX (leucovorin[LV]/fluorouracil[5-FU]/liposomal irinotecan/oxaliplatin) with dose level(s) selected from dose escalation (part 1) in a 28-day cycle.

Intravenous Infusion

Andre navn:
  • ASP3082

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Intravenous Infusion

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Dose Limiting Toxicities (DLTs)
Tidsramme: Up to 28 Days

A DLT is defined as any event meeting the DLT criteria excluding toxicities clearly related to disease progression or intercurrent illness or standard of care (SoC) regimens as determined by the investigator.

Up to 28 Days
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to 48 months

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study IP, whether or not considered related to the study investigational product (IP).

Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study IP. This includes events related to the comparator and events related to the (study) procedures.

Up to 48 months
Number of Participants with Serious Adverse Events (SAEs)
Tidsramme: Up to 48 months

An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other medically important events.

Up to 48 months
Number of Participants with laboratory value abnormalities and/or adverse events (AEs)
Tidsramme: Up to 48 months

Number of participants with potentially clinically significant laboratory values.

Up to 48 months
Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)
Tidsramme: Up to 48 months

Number of participants with potentially clinically significant ECG values.

Up to 48 months
Number of Participants with vital sign abnormalities and/or adverse events (AEs)
Tidsramme: Up to 48 months

Number of participants with potentially clinically significant vital sign values.

Up to 48 months
Number of Participants with physical exam abnormalities and/or adverse events
Tidsramme: Up to 48 months

Number of participants with potentially clinically significant physical exam values.

Up to 48 months
Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status
Tidsramme: Up to 48 months

The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

Up to 48 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Tidsramme: Up to 48 months

ORR is defined as the proportion of participants whose best overall response is rated as complete response (CR) or partial response (PR) per RECIST v1.1.

Up to 48 months
Duration of Response (DOR) per RECIST v 1.1
Tidsramme: Up to 48 months

DOR is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date of documented radiological disease progression per RECIST v1.1 or death in the absence of progression.

Up to 48 months
Disease Control Rate (DCR) per RECIST v 1.1
Tidsramme: Up to 48 months

DCR is defined as the proportion of participants whose best overall response is rated as CR, PR or SD based on RECIST v1.1.

Up to 48 months
Pharmacokinetics (PK) of ASP3082 in plasma: Area under the concentration-time curve (AUC)
Tidsramme: Up to 48 months

AUC will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: Maximum Concentration (Cmax)
Tidsramme: Up to 48 months

Cmax will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)
Tidsramme: Up to 48 months

Ctrough will be recorded from the PK plasma samples collected.

Up to 48 months
PK of ASP3082 in plasma: Time of maximum concentration (tmax)
Tidsramme: Up to 48 months

tmax will be recorded from the PK plasma samples collected.

Up to 48 months
Changes in Kirsten rat sarcoma (KRAS) viral oncogene homolog G12D in tumor samples
Tidsramme: Up to 48 months

Changes in KRAS G12D in tumor samples will be measured.

Up to 48 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Medical Director, Astellas Pharma Inc

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. juni 2022

Primær fullføring (Antatt)

31. desember 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

16. mai 2022

Først innsendt som oppfylte QC-kriteriene

16. mai 2022

Først lagt ut (Faktiske)

19. mai 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

14. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 3082-CL-0101
  • jRCT2031220738 (Registeridentifikator: jRCT)
  • CTR20250465 (Registeridentifikator: chinaDrugTrials.org.cn)
  • 2022-501590-39-00 (Registeridentifikator: CTIS (EU))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

IPD-delingstidsramme

Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Tilgangskriterier for IPD-deling

Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere